Citations

Clear

16280 citation(s) found for "Yu, David".

Environmental impact of colorectal cancer screening with colonoscopy and multi-target stool DNA (mt-sDNA) testing
Alcock, Rebecca , Kisiel, John B. , Hernandez, Lyndon V. , Delarmente, Benjo A. , Estes, Chris , Bartels, J, Lester, J.F. , Vahdat, Vahab , Limburg, Paul J. , Fendrick, A. Mark , Kisiel, John B , Hernandez, Lyndon V , Delarmente, Benjo A , Estes, Chris , Bartels, Jeff , Vahdat, Vahab , Limburg, Paul J , Fendrick, A Mark , Shaukat, Aasma , Lester, Jason

Mayo Clinic

Health Affairs Scholar | March 4, 2025 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/haschl/qxaf041 | PMID 40078452 Get It

Abstract The substantial carbon footprint imparted by medical services warrants increased attention to their environmental impact. National guideline organizations such as the US Preventive Services Task Force (USPSTF) recommend multiple modalities for average-risk colorectal cancer (CRC) screening with varying resource intensity. The aim of this study was to quantify the environmental burden for 2 of the most used CRC screening modalities, colonoscopy and the multi-target stool DNA (mt-sDNA) test. A validated CRC microsimulation model was used to estimate the number of screening and follow-up tests for a cohort of 1 million average-risk individuals who underwent screening between ages 45 and 75. Component resources used for mt-sDNA, including waste products, energy, and transportation for colonoscopy and mt-sDNA, were collected from January 1, 2023, to January 1, 2024, and converted to carbon-equivalent emissions. Resources used for colonoscopy were captured from the literature. Resources devoted to screening colonoscopy were substantially (59%) higher than those to mt-sDNA, even when including follow-up colonoscopy. Of note, follow-up colonoscopy accounted for the majority (64%) of total emissions for the mt-sDNA screening strategy. Compared with colonoscopy screening, mt-sDNA substantially reduces the carbon emissions attributable to population-level CRC screening. Environmental impact should be included as a factor when choosing among guideline-recommended CRC screening strategies.
Technology Spotlight Use of Mass Spectrometry to Study Antibody Clonality Leads to Identification of Novel Thrombophilia: Monoclonal Gammopathy of Thrombotic Significance
Murray, David , Padmanabhan, Anand

Mayo Clinic

The Hematologist | March 4, 2025 | Volume: 22 | Issue: 2 | Pages: No page available

10.1182/hem.v22.2.2025214 Get It

An Evaluation Into the Robustness of Grading of Pleural Mesothelioma Outside of Specialist Centres
Prabhakaran, Sarita , Hocking, Ashleigh , Irani, Yazad , Hussey, Matthew, Alexeyenko, Andrey , Dobra, Katalin , Micsík, Tamás , Duhig, Edwina , Walts, Ann E. , Vanwalleghem, Lieve, Chhut, Vathana, Roden, Anja C. , Roggli, Victor L., Hertoghs, Marjan, Brčić, Luka , Moffat, David, Klebe, Sonja , Hussey, Matthew, Galateau-Sallé, Françoise

Mayo Clinic

APMIS | March 4, 2025 | Volume: 133 | Issue: 3 | Pages: No page available

10.1111/apm.70006 | PMID 40017229 Get It

ABSTRACTThe 2021 WHO classification of thoracic tumours recommends grading pleural mesothelioma to aid prognostication. Robustness of grading and morphological characterisation is key to its clinical utility, though validation of this grading system has largely been conducted by expert thoracic pathologists. We conducted a survey inviting pathologists across a range of practices and expertise to grade digitised images of 50 epithelioid pleural mesotheliomas that had been graded by an expert in thoracic pathology. We included slides that were considered potentially problematic such as small biopsies, focal necrosis, and rare subtypes that may affect grading (small cell and deciduoid features). Using the Sectra Uniview web viewer, participants were asked to score atypia, mitotic count, and necrosis and choose from a list of cytological and architectural features. Seventy‐four pathologists anonymously participated. There was 90% agreement of consensus scores with expert opinion using the WHO 2‐tier grade and 72% for the 3‐tier nuclear grade but only 70% for nuclear atypia, 56% for mitoses, and 84% for necrosis. Both 3‐tier nuclear grade and WHO 2‐tier grading systems were significantly associated with survival. Our study affirms the overall robustness and utility of grading for pleural mesothelioma, reveals variances, and suggests the need for dedicated training.
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Zarif, Talal El , Denu, Ryan , Abdel‐Wahab, Noha , Freeman, Dory , Hayeck, Salim, Anderson, Élizabeth , Goodman, Rachel , Johnson, Douglas B. , Grynberg, Shirly , Shapira, Ronnie, Kwan, Jennifer M. , Long, Georgina V. , Haykal, Tarek , Kojima, Yuki , Yonemor, Kan, Trevino, Alexandra , Hui, Gavin , Drakaki, Alexandra, El‐Am, Edward , Al‐Hader, Ahmad, Babu, P. Narendra , Li, Mingjia , Jones, N. , Herrera, M., Foderaro, Simone , Kim, Chul , Sackstein, Paul , Desai, Aakash , Smith, Caleb J. , Korolewicz, James , Lopetegui‐Lia, Nerea , Funchain, Pauline , Choudhary, Arrush, Asnani, Aarti , Stukalin, Igor , Gallegos, Jesús Antonio Ocejo , Nusrat, Sanober , Malvar, Carmel, McKay, Rana R. , Neilan, Tomas G. , Naqash, Abdul Rafeh , Baena, Javier , El Zarif, Talal , Goodman, Rachel S , Kim, Chul , Desai, Aakash P , Cortellini, Alessio , Pinato, David J , Navani, Vishal , Ocejo Gallegos, Jesus Antonio , Funchain, Pauline , Long, Georgina V , Naqash, Abdul Rafeh , Grynberg, Shirly , Espinar, Javier Baena , Alaiwi, Sarah Abou , Macaron, Walid , Vasbinder, Alexi L. , Woodford, Rachel , Dent, Susan , Kojima, Yuki, Tandon, Ankita, Akhter, Nausheen , Yang, Eric H. , Kozaily, Elie , Farhat, Elias Bou , Mittra, Arjun , Jones, Nicholas, Baena, Javier, Nana, Frank Aboubakar , Parikh, Kaushal , Cortellini, Alessio , Pinato, David J. , Meyers, Daniel E. , Trent, Jonathan C. , Choueiri, Toni K. , Korolewicz, James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 3, 2025 | Volume: 13 | Issue: 3 | Pages: e009364

10.1136/jitc-2024-009364 | PMID 40032601 Get It

Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline. Patients who had received ≥1 dose of ICI were included. Treatment-related adverse events (trAEs) were graded per Common Terminology Criteria for Adverse Event V.5.0. Objective response rates (ORR) were evaluated by Response Evaluation Criteria in Solid Tumors V.1.1 when available. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Results Among 110 pts, median age at ICI initiation was 65 (IQR: 59–75). Median follow-up time since ICI initiation was 36 (95% CI: 26 to 51) months. Melanoma (38%, n=42) and non-small cell lung cancer (24%, n=26) were the most common. 68 (62%) patients received ICIs as first-line, and 29 (26%) patients were treated with combination anti-programmed death-1 and anti-cytotoxic T-lymphocyte antigen 4. The most common location of cardiac metastasis was in the atria (37%, n=41) and ventricles (35%, n=39). 15 patients (13.6%) had bilateral cardiac/pericardial metastasis, 44 (40%) had left-sided, and 43 (39.8%) had right-sided. At ICI initiation, 21% (n=23) had a cardiac thrombus. Cardiology referrals and cardiac MRIs at the time of cancer diagnosis were completed on 58 (53%) and 52 (47%) patients, respectively. Cardiac events occurred in 40 (36%) patients, including arrhythmias (n=14, 13%), arterial/venous emboli (n=4, 3.6%), and cardiac tamponade (n=3, 2.7%). 53 (47%) patients developed trAEs; most common were colitis/diarrhea (n=16, 15%), dermatitis (n=13, 12%), and hepatitis (n=9, 8.2%). ICI-related major cardiac trAEs occurred in 2 (1.8%) patients. 22 patients (20%) developed grade ≥3 trAE. Patients with multiple cardiac metastases had significantly lower responses to ICI-based regimens compared with patients with single cardiac metastasis (11% vs 63%, p=0.02). For melanoma, ORR, median PFS, and median OS were 38%, 9.0 months, and 28.9 months, respectively. 83% of patients with melanoma had concordant responses in overall disease burden and cardiac disease. 91 patients discontinued ICIs, and the main reason was progression or death in 55 (49%) patients. Conclusions Among patients with pre-existing cardiac metastasis, ICIs demonstrated meaningful clinical efficacy with no increase in safety signals. Most patients had concordant responses in the overall disease burden and cardiac mass. Multidisciplinary teams are crucial for the appropriate management of patients with cardiac metastasis.
Brain aging shows nonlinear transitions, suggesting a midlife “critical window” for metabolic intervention
Antal, Botond , Nieuwenhuizen, Helena van , Jones, David T. , Clarke, Kieran , Weistuch, Corey , Ratai, Eva‐Maria , Dill, Ken A. , Mujica‐Parodi, Lilianne R. , Jones, David T , Dill, Ken A , Mujica-Parodi, Lilianne R , Chesebro, Anthony G. , Strey, Helmut H.

Mayo Clinic

Proceedings of the National Academy of Sciences | March 3, 2025 | Volume: 122 | Issue: 10 | Pages: No page available

10.1073/pnas.2416433122 | PMID 40030017 Get It

Understanding the key drivers of brain aging is essential for effective prevention and treatment of neurodegenerative diseases. Here, we integrate human brain and physiological data to investigate underlying mechanisms. Functional MRI analyses across four large datasets (totaling 19,300 participants) show that brain networks not only destabilize throughout the lifetime but do so along a nonlinear trajectory, with consistent temporal “landmarks” of brain aging starting in midlife (40s). Comparison of metabolic, vascular, and inflammatory biomarkers implicate dysregulated glucose homeostasis as the driver mechanism for these transitions. Correlation between the brain’s regionally heterogeneous patterns of aging and gene expression further supports these findings, selectively implicating GLUT4 (insulin-dependent glucose transporter) and APOE (lipid transport protein). Notably, MCT2 (a neuronal, but not glial, ketone transporter) emerges as a potential counteracting factor by facilitating neurons’ energy uptake independently of insulin. Consistent with these results, an interventional study of 101 participants shows that ketones exhibit robust effects in restabilizing brain networks, maximized from ages 40 to 60, suggesting a midlife “critical window” for early metabolic intervention.
Recommendations for use of extracorporeal shockwave therapy in sports medicine: an international modified Delphi study
Singh, Mani, Maffulli, Nicola , Saxena, Amol , Leal, Carlos , Gerdesmeyer, Ludger , Quirologico, Kristina, Furia, John P. , Zwerver, Johannes , Huang, Shih‐Wei , Jarnagin, Johnny, Ruiz, Joseph C. , Noble-Taylor, Kayle E, Al-Khawashki, Hazem , Blatz, Brice W., Borg‐Stein, Joanne , Borowski, Lauren , Bowen, Jay E., Chin, Michael D. , Conenello, Robert M, Fredericson, Michael , Fullem, Brian, Hollander, Karsten , Jelsing, Elena J., Langer, Paul R., Meron, Adele, Monaco, Robert, Paul, Rowan V, Raiser, Sara , Ratcliff, James W, Sampson, Steven , Schaden, Wolfgang , Spector, Jay, Sun, Wei , Syrop, Isaac P., Takahashi, Kenji, Tan, Benedict , Wyss, James F. , Zin, Dan, Hoo, Jennifer Soo , Tenforde, Adam S. , Maffulli, Nicola , Saxena, Amol , Liao, Chun-De , Moya, Daniel , Fredericson, Michael , Hollander, Karsten , Raiser, Sara , Tenforde, Adam S , Rhim, Hye Chang , Robinson, David M. , Ruiz, Joseph, Noble-Taylor, Kayle E., Chin, Michael, Conenello, Robert M., Silbernagel, Karin Grävare , Mautner, Kenneth , Paul, Rowan V, Spector, Jay

Mayo Clinic

British Journal of Sports Medicine | March 3, 2025 | Volume: 59 | Issue: 18 | Pages: 1287-1301

10.1136/bjsports-2024-109082 | PMID 40032293 Get It

Objectives While extracorporeal shockwave therapy (ESWT) may be an efficacious adjunctive treatment option for musculoskeletal injuries, current research is limited by significant heterogeneity within treatment protocols. This study aims to establish international expert consensus recommendations on ESWT terminology, parameters, procedural considerations, contraindications and side effects in the application of ESWT to sports injuries. Methods A systematic literature search was performed on the use of ESWT for musculoskeletal and sports medicine injuries to identify potential panellists, followed by the development of a steering committee-led questionnaire. A three-stage, modified Delphi questionnaire was provided to a panel of 41 international clinical and research experts across 13 countries. Panellists had the opportunity to suggest edits to existing statements or recommend additional statements in Round 1. Consensus was defined as≥75% agreement. Results All 41 panellists completed Rounds 1, 2 and 3. Consensus was reached on 69/118 statements (58.5%), including recommendations on terminology and fundamental concepts, indications for use, procedural aspects for tendinopathy and bone pathologies, treatment correlations with imaging, periprocedural and postprocedural considerations, absolute and relative contraindications and potential side effects. Of the 49 statements that did not reach consensus, 17/49 (34.7%) were related to procedural aspects of bone pathology. Conclusion This international panel presents recommendations on ESWT terminology, indications and treatment considerations to guide ESWT use and decision-making by sports medicine clinicians. While our panel supported the use of ESWT in the treatment of bone pathologies, certain procedural aspects of ESWT specific to these injuries did not reach consensus and require further investigation.
Personalized Tumor-Specific Amplified DNA Junctions in Peripheral Blood of Patients with High-Grade Gliomas
Ali, Mohamed F. , Riviere-Cazaux, Cécile , Johnson, Sarah H. , Salvatori, Rebecca , Penheiter, Alan R. , Smadbeck, James , Murphy, Stephen J. , Harris, Faye R. , McCune, Lex F. , Carlstrom, Lucas P. , Barrett, Michael T. , Kosari, Farhad , Jones, Leila A. , Quiñones‐Hinojosa, Alfredo , Porter, Alyx B. , Mrugała, Maciej M. , Jaeckle, Kurt A. , Anastasiadis, Panos Z. , Kizilbash, Sani H. , Cheville, John C. , Vasmatzis, George , Smadbeck, James B , Ida, Cristiane M , Borad, Mitesh J , Bendok, Bernard R , Quinones-Hinojosa, Alfredo , Porter, Alyx , Mrugala, Maciej M , Jaeckle, Kurt A , Anastasiadis, P Z , Kizilbash, Sani H , Cheville, John C , Routman, David M , Burns, Terry C , Vasmatzis, George , Harris, Faye R. , Ida, Cristiane M. , Borad, Mitesh J. , Bendok, Bernard R. , Routman, David M. , Burns, Terry C.

Mayo Clinic

Clinical Cancer Research | February 28, 2025 | Volume: 31 | Issue: 9 | Pages: 1700-1710

10.1158/1078-0432.ccr-24-3233 | PMID 40019927 Get It

Abstract Purpose: Monitoring disease progression in patients with high-grade gliomas (HGG) is challenging due to treatment-related changes in imaging and the requirement for neurosurgical intervention to obtain diagnostic tissue. DNA junctions in HGG often amplify oncogenes, making these DNA fragments potentially more abundant in blood than monoallelic mutations. In this study, we piloted a cell-free DNA approach for disease detection in the plasma of patients with HGG by leveraging patient-specific DNA junctions associated with oncogene amplifications. Experimental Design: Whole-genome sequencing of grade 3 or 4 isocitrate dehydrogenase–mutant or wild-type astrocytomas was utilized to identify amplified junctions. Individualized qPCR assays were developed using patient-specific primers designed for the amplified junction. ctDNA levels containing these junctions were measured in patient plasma samples. Results: Unique amplified junctions were evaluated by individualized semi-qPCR assays in presurgical plasma of 18 patients, 15 with tumor-associated focal amplifications and three without tumor-associated focal amplifications. high copy-number junctions were robustly detected in the plasma of 14 of 15 (93.3%) patients with amplified junctions and none of the controls. Changes in junction abundance correlated with disease trajectory in serial plasma samples from five patients, including increased abundance of amplified junctions preceding radiographic disease progression. Conclusions: In patients with grade 3 or 4 astrocytomas who had tumor-associated amplifications, patient-specific amplified junctions were successfully detected in assayed plasma from most patients. Longitudinal analysis of plasma samples correlated with disease trajectory, including cytoreduction and progression.
Use and safety of corticosteroid injections in joints and musculoskeletal soft tissue: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, the American Society of Interventional Pain Physici
Benzon, Honorio T. , Provenzano, David , Nagpal, Ameet , Souza, Dmitri , Eckmann, Maxim , Nelson, Ariana M. , Mina, Maged, Elmofty, Dalia , Pino, Carlos A. , Rana, Maunak V., Shah, Shalini , Stout, Alison , Smith, Elizabeth Reichert , Hirsch, Joshua A , Schneider, Byron J. , Manchikanti, Laxmaiah , Maus, Timothy P. , Rivera, Jessica , FitzGerald, John , Provenzano, David Anthony , Chadwick, Andrea , Doshi, Tina L , Pino, Carlos A , Shankar, Hariharan , Cohen, Steven P , Narouze, Samer , Shanthanna, Harsha , Hunt, Christine , Benzon, Honorio T , Nagpal, Ameet S , FitzGerald, John D , Nelson, Ariana M , Abd-Elsayed, Alaa A , Doshi, Tina L , Shankar, Hariharan , Smith, Elizabeth, Abdi, Salahadin , Cohen, Steven P. , Narouze, Samer , Shanthanna, Harsha , Wasan, Ajay D. , Hoang, Thanh D , Rivera, Jessica

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 27, 2025 | Volume: 51 | Issue: 7 | Pages: 746-773

10.1136/rapm-2024-105656 | PMID 40015722 Get It

Background Intra-articular corticosteroid (IACS) injection and peri-articular corticosteroid injection are commonly used to treat musculoskeletal conditions. Results vary by musculoskeletal region, but most studies report short-term benefit with mixed results on long-term relief. Publications showed adverse events from single corticosteroid injections. Recommended effective doses were lower than those currently used by clinicians. Methods Development of the practice guideline for joint injections was approved by the Board of Directors of the American Society of Regional Anesthesia and Pain Medicine and the participating societies. A Corticosteroid Safety Work Group coordinated the development of three guidelines: peripheral nerve blocks and trigger points; joints; and neuraxial, facet, and sacroiliac joint injections. The topics included safety of the technique in relation to landmark-guided, ultrasound-guided, or radiology-aided injections; effect of the addition of the corticosteroid on the efficacy of the injectate; and adverse events related to the injection. Experts on the topics were assigned to extensively review the literature and initially develop consensus statements and recommendations. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. A modified Delphi process was adhered to in arriving at a consensus. Results This guideline focuses on the safety and efficacy of corticosteroid joint injections for managing joint chronic pain in adults. The joints that were addressed included the shoulder, elbow, hand, wrist, hip, knee, and small joints of the hands and feet. All the statements and recommendations were approved by all participants and the Board of Directors of the participating societies after four rounds of discussion. There is little evidence to guide the selection of one corticosteroid over another. Ultrasound guidance increases the accuracy of injections and reduces procedural pain. A dose of 20 mg triamcinolone is as effective as 40 mg for both shoulder IACS and subacromial subdeltoid bursa corticosteroid injections. The commonly used dose for hip IACS is 40 mg triamcinolone or methylprednisolone. Triamcinolone 40 mg is as effective as 80 mg for knee IACS. Overall, IACS injections result in short-term pain relief from a few weeks to a few months. The adverse events include an increase in blood glucose, adrenal suppression, detrimental effect on cartilage lining the joint, reduction of bone mineral density, and postoperative joint infection. Conclusions In this practice guideline, we provided specific recommendations on the role of corticosteroids in joint, bursa, and peritendon injections for musculoskeletal pain.
Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes
Collin, Lindsay J. , Cushing‐Haugen, Kara L. , Terry, Kathryn L. , Goode, Ellen L. , Wu, Anna H. , Harris, Holly R. , Sasamoto, Naoko , Cramer, Daniel W. , Modugno, Francesmary , Elishaev, Esther , Moysich, Kirsten B. , Fasching, Peter A. , Pearce, Celeste Leigh , Menon, Usha , Gayther, Simon A. , Wentzensen, Nicolas , Goodman, Marc T. , George, Joshy , Talhouk, Aline , Anglesio, Michael S. , Ramus, Susan J. , Bowtell, David D.L. , Tworoger, Shelley S. , Schildkraut, Joellen M. , George, Joshy , Fu, Zhuxuan , Moysich, Kirsten , Fasching, Peter A , Pearce, Celeste Leigh , Menon, Usha , Gentry‐Maharaj, Aleksandra , Gayther, Simon A , Wentzensen, Nicolas , Goodman, Marc T , George, Joshy , Talhouk, Aline , Anglesio, Michael S , Ramus, Susan J , Bowtell, David D , Tworoger, Shelley S , Schildkraut, Joellen M , Webb, Penelope M , Doherty, Jennifer A , Cramer, Daniel W , Modugno, Francesmary , Harris, Holly R , Elishaev, Esther , Cushing-Haugen, Kara L , Fu, Zhuxuan , Webb, Penelope M. , Doherty, Jennifer A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 26, 2025 | Volume: 34 | Issue: 5 | Pages: 762-773

10.1158/1055-9965.epi-24-1143 | PMID 40009771 Get It

Abstract Background: Ovarian high-grade serous carcinomas (HGSC) comprise four distinct molecular subtypes based on mRNA expression patterns, with differential survival. Understanding risk factor associations is important to elucidate the etiology of HGSC. We investigated associations between different epidemiologic risk factors and HGSC molecular subtypes. Methods: We pooled data from 11 case–control studies with epidemiologic and tumor gene expression data from custom NanoString CodeSets developed through a collaboration within the Ovarian Tumor Tissue Analysis consortium. The PrOTYPE-validated NanoString-based 55-gene classifier was used to assign HGSC gene expression subtypes. We examined associations between epidemiologic factors and HGSC subtypes in 2,070 cases and 16,633 controls using multivariable-adjusted polytomous regression models. Results: Among the 2,070 HGSC cases, 556 (27%) were classified as C1.MES, 340 (16%) as C5.PRO, 538 (26%) as C2.IMM, and 636 (31%) as C4.DIF. The key factors, including oral contraceptive use, parity, breastfeeding, and family history of ovarian cancer, were similarly associated with all subtypes. Heterogeneity was observed for several factors. Former smoking [OR = 1.25; 95% confidence interval (CI) = 1.03, 1.51] and genital powder use (OR = 1.42; 95% CI = 1.08, 1.86) were uniquely associated with C2.IMM. History of endometriosis was associated with C5.PRO (OR = 1.46; 95% CI = 0.98, 2.16) and C4.DIF (OR = 1.27; 95% CI = 0.94, 1.71) only. Family history of breast cancer (OR = 1.44; 95% CI = 1.16, 1.78) and current smoking (OR = 1.40; 95% CI = 1.11, 1.76) were associated with C4.DIF only. Conclusions: This study observed heterogeneous associations of epidemiologic and modifiable factors with HGSC molecular subtypes. Impact: The different patterns of associations may provide key information about the etiology of the four subtypes.
Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET
Wiste, Heather J. , Weigand, Stephen D. , Therneau, Terry M. , Griswold, Michael , Braunstein, Joel B. , Verghese, Philip B. , Graff‐Radford, Jonathan, Lowe, Val J. , Gunter, Jeffrey L. , Petersen, Ronald C. , Jack, Clifford R. , Jack, Clifford R , Cogswell, Petrice M. , West, Tim , Graff‐Radford, Jonathan , Algeciras‐Schimnich, Alicia , Schwarz, Christopher G. , Senjem, Matthew L. , Knopman, David S. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | February 26, 2025 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14629 | PMID 39989078 Get It

Abstract INTRODUCTION Limited data exist on the utility of plasma biomarkers to predict incident abnormal amyloid positron emission tomography (PET). In this study we evaluate the association of plasma Alzheimer's disease (AD) biomarkers with amyloid PET progression among initially amyloid PET negative (A−) individuals. METHODS We included 290 A−, cognitively unimpaired Mayo Clinic Study of Aging participants. We estimated the association of each baseline plasma biomarker with progression from A− to A+ and with rate of amyloid PET change. RESULTS Interquartile range differences in amyloid beta 42/40, percent phosphorylated tau 217 (%p‐tau217), and Amyloid Probability Score 2 were associated with 1.29 ( P = 0.09), 1.38 ( P < 0.001), and 1.20 ( P = 0.05) increases, respectively, in the hazard of progression from A− to A+ and 0.27 ( P = 0.16), 0.50 ( P = 0.007), and 0.28 ( P = 0.15) Centiloid/year increases, respectively, in annual rate of amyloid PET change. DISCUSSION Plasma %p‐tau217 may be a useful screening tool to enrich for participants with increased likelihood of progressing from normal to abnormal amyloid PET in a primary prevention trial. Highlights Plasma phosphorylated tau 217 was associated with amyloid positron emission tomography progression, negative to positive. The associations were weaker for amyloid beta 42/40 and Amyloid Probability Score 2. Age and apolipoprotein E ε4 carriership were also important predictors. These markers may be useful for enrichment of a primary prevention trial.